Cordlife Group Limited (CLIFF)
Cordlife Group Limited operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Singapore, CE, SG. The stock last traded at $0.15, up 0.00% on the session, giving a market capitalisation of $38.6M. On trailing twelve-month figures it carries a trailing P/E of -2.92, a net margin of -32.0%. Its beta of 0.67 implies it has historically moved less than the broad market.
As an investment holding company, Cordlife Group Limited offers cord blood banking solutions across various countries including Singapore, Hong Kong, India, Malaysia, and the Philippines, extending its reach globally. Its operations are structured into two distinct segments: Banking and Diagnostics. The Banking segment is dedicated to the processing and secure storage of stem cells derived from cord blood, cord lining, and cord tissue. Meanwhile, its Diagnostics arm delivers a suite of screening services, such as non-invasive prenatal testing, pediatric vision evaluations, and genetic and metabolic screenings for newborns. Furthermore, Cordlife extends its diagnostic offerings to include specialized procedures like preimplantation genetic screening, endometrial receptivity testing, pediatric allergen analysis, and genetic talent assessments. It also supports parents through "moms up," a mobile application providing valuable resources for pregnancy and parenting. Beyond its core medical services, the company engages in management, marketing, and property investment activities. Established in 2001, Cordlife Group Limited maintains its corporate headquarters in Singapore.
Cordlife Group Limited is most often compared with the following Healthcare names: